EQRx and AbCellera announced a collaboration agreement for the discovery and development of therapeutic antibodies. The collaboration will leverage AbCellera's AI-powered antibody discovery technology to search and analyze natural immune responses to identify novel antibody drug candidates for multiple targets. The partnership, which spans several therapeutic areas, will help to rapidly expand EQRx's early-stage pipeline of novel medicines.

The deal also includes the option for additional investment from AbCellera at progressive stages of preclinical development, clinical development, and commercialization in exchange for an increased share of product sales. The initial programs will focus on targets in oncology and immunology.